ATNX Athenex Inc.

11.12
+0.14  (+1%)
Previous Close 10.98
Open 11.04
Price To Book 5.32
Market Cap 907,673,814
Shares 81,625,343
Volume 301,960
Short Ratio
Av. Daily Volume 667,045
Stock charts supplied by TradingView

NewsSee all news

  1. Athenex Announces Participation in the 2020 RBC Capital Markets Global Healthcare Virtual Conference

    BUFFALO, N.Y., May 19, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  2. Athenex, Inc. Reports First Quarter Ended March 31, 2020 Financial Results and Provides Corporate Update

    Regulatory filings for tirbanibulin ointment for actinic keratosis submitted to both FDA and EMA Oral Paclitaxel NDA submission is on track 2020 product sales guidance re-affirmed Conference call & webcast today

  3. Athenex Announces Acceptance of Oral Paclitaxel Phase II Study in Angiosarcoma Abstract at ASCO20 Virtual Scientific Program

    BUFFALO, N.Y., April 29, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  4. Athenex, Inc. to Report First Quarter 2020 Earnings Results on May 7, 2020

    BUFFALO, N.Y., April 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  5. Athenex Provides an Update on Oral Paclitaxel FDA Meeting

    BUFFALO, N.Y., April 09, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b poster at ESMO September 29, 2019.
Oraxol and CYRAMZA (Ramucirumab)
Gastric cancer
PDUFA date December 30, 2020.
Tirbanibulin ointment
Actinic keratosis
Phase 3 data noted PFS (p=0.077) 9.3 months vs 8.3 months. OS (p=0.035) 27.9 months vs 16.9 months. ORR 40.4% vs 25.6%. Meeting with FDA April 2020 with NDA to be filed shortly after.
Oraxol
Metastatic breast cancer
Phase 1/2 initiation announced November 26, 2018.
Oraxol and pembrolizumab (Keytruda)
Solid Tumors
Phase 2 presentation at ASCO May 29, 2020.
Oraxol (Oral Paclitaxel) (ASCO)
Angiosarcoma

Latest News

  1. Athenex Announces Participation in the 2020 RBC Capital Markets Global Healthcare Virtual Conference

    BUFFALO, N.Y., May 19, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  2. Athenex, Inc. Reports First Quarter Ended March 31, 2020 Financial Results and Provides Corporate Update

    Regulatory filings for tirbanibulin ointment for actinic keratosis submitted to both FDA and EMA Oral Paclitaxel NDA submission is on track 2020 product sales guidance re-affirmed Conference call & webcast today

  3. Athenex Announces Acceptance of Oral Paclitaxel Phase II Study in Angiosarcoma Abstract at ASCO20 Virtual Scientific Program

    BUFFALO, N.Y., April 29, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  4. Athenex, Inc. to Report First Quarter 2020 Earnings Results on May 7, 2020

    BUFFALO, N.Y., April 23, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  5. Athenex Provides an Update on Oral Paclitaxel FDA Meeting

    BUFFALO, N.Y., April 09, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  6. Athenex Provides a Corporate Update

    BUFFALO, N.Y., March 13, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  7. Athenex Announces FDA Acceptance for Filing of U.S. NDA for Tirbanibulin Ointment in Actinic Keratosis

    BUFFALO, N.Y., March 09, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  8. Athenex's Partner Almirall Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Tirbanibulin Ointment in Actinic Keratosis

    BUFFALO, N.Y., March 02, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  9. Athenex, Inc. Reports Fourth Quarter and Year Ended December 31, 2019 Financial Results and Provides Corporate Update

    Tirbanibulin ointment NDA for actinic keratosis was submittedOral Paclitaxel NDA submission is on track; Final FDA meeting scheduled for early AprilPresentation of Oral Paclitaxel Phase 3 results at SABCS received broad

  10. Athenex Announces Participation at the Cowen 40th Annual Health Care Conference

    BUFFALO, N.Y., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of

  11. Athenex, Inc. to Report Fourth Quarter and Full Year 2019 Earnings Results on February 27, 2020

    BUFFALO, N.Y., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of

  12. Athenex CEO Informs Shareholders of Unrelated Matter Regarding Past Board Membership at Porton Pharma

    BUFFALO, N.Y., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Today, Dr. Johnson Lau, Chairman and Chief Executive Officer of Athenex, Inc. (NASDAQ:ATNX), informed shareholders he received a notice of a proposed administrative fine

  13. Athenex Expands its Strategic Partnership with Guangzhou Xiangxue Pharmaceutical Through a Licensing Agreement for its Product Candidates Oral Paclitaxel and Oral Irinotecan, as well as Tirbanibulin Ointment, in China, Hong Kong and Macao

    The agreement covers China, Hong Kong and Macao (the "Territory") and represents an expansion of the existing relationship between the two companies. Athenex will receive payments of up to $200 million which include an

  14. Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic Breast Cancer

    First oral taxane to demonstrate superior response rate and overall survival compared to IV paclitaxel in a Phase III clinical trial Data to be presented today in an oral presentation at the 2019 San Antonio Breast

  15. Athenex Announces Details of Investor Event and Webcast at SABCS on December 13, 2019

    BUFFALO, N.Y., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  16. Athenex Announces $60 Million Private Placement

    BUFFALO, N.Y., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  17. Athenex Announces Key Company Activities at San Antonio Breast Cancer Symposium

    Abstract selected for the SABCS press programOral presentation of Oral Paclitaxel and encequidar Phase III results on December 13Company to host a Key Opinion Leader webcast event for the investment community BUFFALO,

  18. Athenex, Inc. Announces Third Quarter 2019 Financial Results

    Oral presentation of Phase III Oral Paclitaxel data at the San Antonio Breast Cancer Symposium NDA submissions for Oral Paclitaxel and tirbanibulin ointment are on track $19.2 million of product sales in Q3 2019, a 45%

  19. Athenex Announces European Commission Grants Orphan Designations for Paclitaxel and Encequidar for the Treatment of Soft Tissue Sarcoma

    BUFFALO, N.Y., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  20. Athenex Announces Progress Update from Partner Almirall on Tirbanibulin Ointment

    BUFFALO, N.Y., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  21. Athenex Completes Construction of New API Facility in Chongqing

    BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  22. Athenex to Present at the 2019 San Antonio Breast Cancer Symposium

    BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  23. Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019

    BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  24. Athenex Announces Initiation of Phase I Clinical Study in China of KX2-361 Oral by Partner Guangzhou Xiangxue Pharmaceutical

    BUFFALO, N.Y., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of

  25. Athenex Announces Appointment of Daniel Lang MD to Lead TCR-T Immunotherapy Operations and Support Corporate Development Strategy

    BUFFALO, N.Y., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of